secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAXCYTE, INC. (MXCT)
CIK:        0001287098
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0001558370-23-009107
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MaxCyte Q1 revenue $8.6M (-26% YoY), net loss $10.9M; cuts FY23 revenue growth guidance to 8-12%
--------------------------------------------------------------------------------

- Total revenue $8.6M, down 26% YoY; core business revenue $7.8M, down 19%.
- Net loss $10.9M vs $4.1M; EBITDA loss $12.2M vs $3.7M.
- FY23 total revenue growth guidance lowered to 8%-12%; core revenue growth 5%-10%.
- Two new SPL partnerships signed: Walking Fish Therapeutics (May) and Catamaran Bio (Jan).
- Douglas J. Swirsky appointed CFO, effective immediately.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1287098/000155837023009107/0001558370-23-009107-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1287098/000155837023009107/mxct-20230510x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-009107

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer